Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AMENDMENT TO LICENSE AGREEMENTLicense Agreement • August 1st, 2019 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT TO the December 21, 2006 LICENSE AGREEMENT (this “Amendment”) is made and entered into this 1st day of August, 2019 (the “Effective Date”), by and between KYOWA KIRIN CO., LTD., a Japanese corporation with its principal offices at 1-9-2 Otemachi, Chiyoda-ku, Tokyo (“Kirin”) and AVEO PHARMACEUTICALS, INC., a Delaware Corporation with its principal offices at 1 Broadway, Cambridge, MA 02142 United States (“Aveo”). Kirin and Aveo may be referred to herein each, individually, as a “Party” or, collectively, as the “Parties.” Capitalized terms used in this Amendment shall have the same meanings given to them in the Agreement (defined below), except as expressly otherwise defined herein.
